Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II non-randomised study of 68Ga-OPS202 PET uptake timing in newly diagnosed breast cancer
2018-000028-33Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Apr 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-satoreotide trizoxetan in breast cancer, sponsored by Ipsen. Primary endpoints: Proportion of women with sstr2-positive breast cancer lesions on 68Ga-OPS202 PET and Optimal uptake time of 68Ga-OPS202 for sstr2-positive lesion imaging. Started Apr 2018; status: terminated.
02
Drugs
68Ga-satoreotide trizoxetan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-000028-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000028-33.